RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..1 of 1 - per page
Order by
Optimised pulmonary and nasal therapies using supercritical fluid (SCF) particle engineering
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Displaying 1..1 of 1 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Type I Diabetes Therapy Area Pipeline Report
Nov 2010 - 281 pages - $1,495
Type II Diabetes Therapy Area Pipeline Report
Nov 2010 - 2034 pages - $1,495
Nucleic Acid Drug Delivery Technologies: Players, products & prospects to 2018 (Volume III)
Jun 2009 - 110 pages - $1,040
Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020
Oct 2011 - 41 pages - $2,000
Diabetes Drug Discoveries 2009: what the future holds
Feb 2009 - 160 pages - $1,390
Clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Apr 2010 - 510 pages - $2,695
The National Institute of Diabetes and Digestive and Kidney Diseases – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
Precose (Type 2 Diabetes) – Analysis and Forecasts to 2020
Oct 2011 - 42 pages - $2,000
Drug Delivery Partnering Terms and Agreements in Pharma and Biotech
Nov 2010 - 428 pages - $2,695
ASP1941 (Type 2 Diabetes) – Analysis and Forecasts to 2020
Oct 2011 - 44 pages - $2,000
More Related Market Research Reports >>>

Your selection

Industry sector
Drug delivery del
Therapeutic target
Metabolism del
Diabetes type II del
Development phase
Phase III/IV del

Browse By

Industry sector
Intravesical
Nasal
Nasal topical
Ophthalmic
Oral liquid
Oral solid
Otic
Parenteral
Pulmonary
Rectal
Systemic
Topical
Vaginal

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us